Viral Genetics Subsidiary VG Energy Featured On EnergyBoom.com

VG Energy, a subsidiary of Viral Genetics, Inc., (Pink Sheets: VRAL) has been featured by the website EnergyBoom.com. A recent story highlighted the company’s new green energy solution—an additive that causes algae and other plants to significantly increase the production of fats that may be used as a fuel source.

EnergyBoom is a global leader in news information about the renewable energy sector, offering expert analysis about the renewable energy world. EnergyBoom.com claims that advertisers reach, "millions of thought-leaders in the renewable energy community.”

The story is posted at: http://www.energyboom.com/biofuels/has-vg-energy-stumbled-elusive-"lipid-trigger”

Titled, Has VG Energy Stumbled on the Elusive Algae "Lipid Trigger?”, the December 9 story by Mitchell Anderson quotes VG Energy advisory board member John Sheehan as saying:

"What they have stumbled on indirectly through a fairly unrelated field of research is the possibility that you really can turn on lipid production in algae,” said Sheehan. "For the last five years of the research at the National Renewable Energy Lab, we were entirely focused on exactly this question.”

Sheehan has spent nearly two decades working on biofuels, including coordinating bio-fuel research at the University of Minnesota’s Institute on the Environment and consulting to clients in biotechnology and renewable energy.

According to VG Energy’s Senior Vice President Monica Ord, "VG Energy’s lead scientist Dr. M. Karen Newell’s most recent work has shown that the technology raises lipid levels significantly in algae, and also in yeast, soy, grasses, and other plants, with no genetic modification or death of the plant source. The ramifications of this are extensive. Our focus now with John Sheehan’s expertise is to discuss and partner with the companies that can start to implement this technology into their research in the quickest and largest scale possible. We share a sense of urgency with the public at large and are thrilled to be able to make a difference in the biofuel realm."

About VG Energy, Inc.

VG Energy Inc. is an alternative energy and agricultural biotech company that is a majority-owned subsidiary of Viral Genetics Inc., a biotechnology company researching new treatments and methods of detection for diseases including cancer, HIV/AIDS and others. Using its Metabolic Disruption technology ("MDT”), Viral Genetics’ cancer research led to discoveries with major consequences in a wide variety of other industries, including bio-fuel and vegetable oils. VG Energy Inc. holds the exclusive worldwide rights to the licensed MDT patents for us in the increase of production of various plant-derived oils from algae and seeds. Importantly, these pivotal discoveries promise to allow the biofuel industry to overcome its major obstacle in the area of production efficiency: namely an increase in production yields leading to feasible economic returns on investment allowing renewable biodiesel to be competitive with fossil fuels. Online at www.vgenergy.org.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports. None of Viral Genetics’ drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.